



# Electronic Information Disclosure Statement

## TRPM-2 Antisense Therapy USing an Oligonucleotide Having 2'-O-(2-methoxyethyl) modifications

Application:



10/080794

Confirmation:

2924

Applicant(s):

Martin Gleave

Docket Number:

UBC.P-020-3

Group Art Unit:

1632

Examiner:

search string:

( 6383808 ).pn.

### US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

Init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
NP01	6383808	2002-05-07		Monia et al.	435	375	

### Signature

Examiner Name	Date
	10/23/2004



ATTORNEY DOCKET NO. UBC.P-020-3

RECEIVED  
JUN 26 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Application No: 10/080,794  
Filing Date: February 22, 2002  
First Named Inventor: Gleave, et al.  
Confirmation No.: 2924  
Group Art Unit: 1635  
Examiner Name: LaCourciere, Karen A.  
Attorney Docket No.: UBC.P-020-3

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Office	Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages where relevant passages appear
<i>Kae</i>	WO	00/49937 A2	The University of British Columbia	Aug. 31, 2000	

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner: Karen A. LaCourciere Date Considered: 10/23/2004

RECEIVED

# 7/Scanned  
I.D.S.

MAR 27 2003  
PATENT & TRADEMARK OFFICE

Institute for form 1449  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

MAR 31 2003

TECH CENTER 1800/2000

Application No.: 10/080,794

Applicant: Gleave, et al.

Filing Date: 02/22/2002

Conf. No.: 2924

Title: TRPM-2 Antisense Therapy

Attorney Docket No.:

UBC.P-020-3

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
HGC	5,789,389	Tarasewicz et al.	08/04/1998
HGC	6,335,194 B1	Bennett et al.	01/01/2002

FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
HGC	WO 01/46455 A2	Yale University	06/28/2001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
HGC	Nör et al.; Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; Cancer Research; Vol. 61; March 1, 2001; 2183-2188.
	Kirby et al.; Bartonella-Associated Endothelial Proliferation Depends on Inhibition of Apoptosis; PNAS; Vol. 99, No. 7; April 2, 2002; 4656-4661.
	Cox et al.; Angiogenesis and Non-Small Cell Lung Cancer; Lung Cancer; Vol. 27, 2000; 81-100.
	Tran et al.; A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF; PNAS; Vol. 99, No. 7; April 2, 2002; 4349-4354.
	Nör et al.; Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice; Laboratory Investigation; Vol. 81, No.4; April 2001; 453-463.
	Boral et al.; Clinical Evaluation of Biologically Targeted Drugs: Obstacles and Opportunities; Cancer Chemother Pharmacol; Vol. 42; 1998; S3-S21.

RECEIVED

MAR 31 2003

Substitute for form 1449




**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Application No.: 10/080,794  
Applicant: Gleave, et al. TECH CENTER 1800/2900  
Filing Date: 02/22/2002  
Conf. No.: 2924  
Title: TRPM-2 Antisense Therapy  
Attorney Docket No.: UBC.P-020-3

Page 2 of 2

HAC	Zwain et al.; Clusterin Protects Granulosa Cells from Apoptotic Cell Death During Follicular Atresia; Experimental Cell Research; Vol. 257; 2000; 101-110.
HAC	Lee et al.; In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator; The Prostate Supplement; Vol. 9; 2000; 21-24.
HAC	Genta Incorporated; New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment; <a href="http://www.genta.com">www.genta.com</a> ; 2001.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

  
Examiner Signature

10/23/2004  
Date Considered